210 related articles for article (PubMed ID: 35609174)
1. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M; Ferrada MA; Koster MJ; Barba T; Gerfaud-Valentin M; Mékinian A; Coelho H; Fossard G; Barraco F; Galicier L; Bienvenu B; Hirsch P; Vial G; Boutin AB; Galland J; Le Guenno G; Bigot A; Warrington KJ; Kermani TA; Grayson PC; Patel BA; Beck DB; Jamilloux Y; Fenaux P; Sujobert P
Blood; 2022 Aug; 140(8):927-931. PubMed ID: 35609174
[TBL] [Abstract][Full Text] [Related]
2. Heiblig M, Ferrada MA, Koster MT, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140(8):927-931.
Blood; 2023 Mar; 141(13):1647. PubMed ID: 36995697
[No Abstract] [Full Text] [Related]
3. Ruxolitinib takes center stage for VEXAS syndrome.
Conway R
Blood; 2022 Aug; 140(8):807-808. PubMed ID: 36006674
[No Abstract] [Full Text] [Related]
4. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Rojas P; Sarmiento M
Acta Haematol; 2021; 144(3):314-318. PubMed ID: 32726783
[TBL] [Abstract][Full Text] [Related]
6. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
Hunter AM; Newman H; Dezern AE; Steensma DP; Niyongere S; Roboz GJ; Mo Q; Chan O; Gerds A; Sallman DA; Dominguez-Viqueira W; Letson C; Balasis ME; Ball M; Kruer T; Zhang H; Lancet JE; List AF; Sekeres MA; Komrokji RS; Padron E
Clin Cancer Res; 2021 Nov; 27(22):6095-6105. PubMed ID: 34253584
[TBL] [Abstract][Full Text] [Related]
7. Clinically used JAK inhibitor blunts dsRNA-induced inflammation and calcification in aortic valve interstitial cells.
Parra-Izquierdo I; Sánchez-Bayuela T; Castaños-Mollor I; López J; Gómez C; San Román JA; Sánchez Crespo M; García-Rodríguez C
FEBS J; 2021 Nov; 288(22):6528-6542. PubMed ID: 34009721
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
[No Abstract] [Full Text] [Related]
9. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
11. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
13. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.
de Valence B; Delaune M; Nguyen Y; Jachiet V; Heiblig M; Jean A; Riescher Tuczkiewicz S; Henneton P; Guilpain P; Schleinitz N; Le Guenno G; Lobbes H; Lacombe V; Ardois S; Lazaro E; Langlois V; Outh R; Vinit J; Martellosio JP; Decker P; Moulinet T; Dieudonné Y; Bigot A; Terriou L; Vlakos A; de Maleprade B; Denis G; Broner J; Kostine M; Humbert S; Lifermann F; Samson M; Pechuzal S; Aouba A; Kosmider O; Dion J; Grosleron S; Bourguiba R; Terrier B; Georgin-Lavialle S; Fain O; Mekinian A; Morgand M; Comont T; Hadjadj J;
Ann Rheum Dis; 2024 Feb; 83(3):372-381. PubMed ID: 38071510
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
15. Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors.
Picca A; Valyraki N; Birzu C; Kramkimel N; Hermine O; Zahr N; Berzero G; Psimaras D
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34497101
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
Lobo PB; Guisado-Hernández P; Villaoslada I; de Felipe B; Carreras C; Rodriguez H; Carazo-Gallego B; Méndez-Echevarria A; Lucena JM; Aljaro PO; Castro MJ; Noguera-Uclés JF; Milner JD; McCann K; Zimmerman O; Freeman AF; Lionakis MS; Holland SM; Neth O; Olbrich P
J Clin Immunol; 2022 Aug; 42(6):1193-1204. PubMed ID: 35507130
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
King B; Lee AI; Choi J
J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
[No Abstract] [Full Text] [Related]
18. The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis.
Overstreet AM; LaTorre DL; Abernathy-Close L; Murphy SF; Rhee L; Boger AM; Adlaka KR; Iverson AM; Bakke DS; Weber CR; Boone DL
Mucosal Immunol; 2018 Sep; 11(5):1454-1465. PubMed ID: 29988117
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
20. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
